EZER™ CRP/MxA Combo Rapid Test CE
€0.00
In stock
SKU
P231123
INTENDED USE
The EZERTM CRP/MxA Combo Rapid Test is a lateral flow chromatographic immunoassay for the qualitative detection of Myxovirus resistance protein A (MxA) and C-reactive protein (CRP) in human whole blood. This test aids in identification of viral and/or bacterial infection in patients with clinical symptoms caused by infection. The assessment of whether a bacterial infection is present should always be based on consideration of all available information, and not based solely on the test results. For in vitro diagnostic use only.
BACKGROUND
Acute respiratory infections (ARIs), which includes acute uncomplicated bronchitis, pharyngitis, rhinosinusitis, the common cold and influenza, affect 20% of the population each year. Due to the apparent overlap of ARI symptoms, it is difficult for physicians to differentiate viral and/or bacterial infections based on symptoms, to the detriment of antibiotic therapy1. Myxovirus resistance protein A (MxA) is an interferon-induced GTPase, the level of which increases rapidly during acute viral infections. MxA has a low basal concentration of less than 15 ng/mL, a fast induction time of 1-2 hours, and a long half-life of 2.3 days2. Therefore, MxA level can be directly taken as a deal marker in response to acute viral infection3. CRP is a non-specific acute temporal response protein with extremely low levels in normal health, and CRP levels are significantly elevated within 4-6 hours of bacterial infection and peaks after 36 hours, while viral infections have a weak effect on them, thus CRP can be used as a typical indicator of bacterial infection4. CRP/MxA Combo Rapid Test simultaneously detects elevated levels of MxA and CRP to help identify patients suffering from clinically significant ARI as well as differentiate viral from bacterial infection.
PRINCIPLE
The test is ready to use and is based on a membrane technology with colloidal gold nanoparticles. Our kit is aimed to the detection of Myxovirus resistance protein A (MxA) and C-reactive protein (CRP) from whole blood. Each pouch contains one lateral-flow strips for the identification of MxA and CRP.
A nitrocellulose membrane is sensitised with:
(1) a monoclonal antibody directed against MxA (“MxA” line)
(2) a monoclonal antibody directed against CRP (“CRP” line)
(3) a control capture reagent (upper “C” line).
Three different colloidal gold nanoparticles conjugatesare dried on a membrane: a conjugate directed againstMxA, a conjugate directed against CRP and a control conjugate.
When the whole blood and the buffer comes into contact with the strip, the solubilised conjugates migrate with the sample by passive diffusion, while conjugates and sample material come into contact with the immobilised respective antibodies that are adsorbed onto the nitrocellulose strip. If the MxA of sample exceeds 40 ng/mL and the CRP exceeds 20 μg/mL. the respective complexes made of the conjugates and either MxA or CRP will remain bound to their respective specific lines (MxA: “MxA” line, CRP: “CRP” line). The migration continues by passive diffusion and both conjugates and sample material come into contact with the (upper) line control reagent that binds a control conjugate (“C” line), thereby producing a red line. The result is visible within 15 minutes in the form of red lines on the strip
The EZERTM CRP/MxA Combo Rapid Test is a lateral flow chromatographic immunoassay for the qualitative detection of Myxovirus resistance protein A (MxA) and C-reactive protein (CRP) in human whole blood. This test aids in identification of viral and/or bacterial infection in patients with clinical symptoms caused by infection. The assessment of whether a bacterial infection is present should always be based on consideration of all available information, and not based solely on the test results. For in vitro diagnostic use only.
BACKGROUND
Acute respiratory infections (ARIs), which includes acute uncomplicated bronchitis, pharyngitis, rhinosinusitis, the common cold and influenza, affect 20% of the population each year. Due to the apparent overlap of ARI symptoms, it is difficult for physicians to differentiate viral and/or bacterial infections based on symptoms, to the detriment of antibiotic therapy1. Myxovirus resistance protein A (MxA) is an interferon-induced GTPase, the level of which increases rapidly during acute viral infections. MxA has a low basal concentration of less than 15 ng/mL, a fast induction time of 1-2 hours, and a long half-life of 2.3 days2. Therefore, MxA level can be directly taken as a deal marker in response to acute viral infection3. CRP is a non-specific acute temporal response protein with extremely low levels in normal health, and CRP levels are significantly elevated within 4-6 hours of bacterial infection and peaks after 36 hours, while viral infections have a weak effect on them, thus CRP can be used as a typical indicator of bacterial infection4. CRP/MxA Combo Rapid Test simultaneously detects elevated levels of MxA and CRP to help identify patients suffering from clinically significant ARI as well as differentiate viral from bacterial infection.
PRINCIPLE
The test is ready to use and is based on a membrane technology with colloidal gold nanoparticles. Our kit is aimed to the detection of Myxovirus resistance protein A (MxA) and C-reactive protein (CRP) from whole blood. Each pouch contains one lateral-flow strips for the identification of MxA and CRP.
A nitrocellulose membrane is sensitised with:
(1) a monoclonal antibody directed against MxA (“MxA” line)
(2) a monoclonal antibody directed against CRP (“CRP” line)
(3) a control capture reagent (upper “C” line).
Three different colloidal gold nanoparticles conjugatesare dried on a membrane: a conjugate directed againstMxA, a conjugate directed against CRP and a control conjugate.
When the whole blood and the buffer comes into contact with the strip, the solubilised conjugates migrate with the sample by passive diffusion, while conjugates and sample material come into contact with the immobilised respective antibodies that are adsorbed onto the nitrocellulose strip. If the MxA of sample exceeds 40 ng/mL and the CRP exceeds 20 μg/mL. the respective complexes made of the conjugates and either MxA or CRP will remain bound to their respective specific lines (MxA: “MxA” line, CRP: “CRP” line). The migration continues by passive diffusion and both conjugates and sample material come into contact with the (upper) line control reagent that binds a control conjugate (“C” line), thereby producing a red line. The result is visible within 15 minutes in the form of red lines on the strip
| Is Featured? | No |
|---|
Write Your Own Review